OTEurope

Novel glaucoma solution enters trials

Oct 20, 2008

INS117548, a solution designed to treat glaucoma, has entered Phase I clinical trials, according to an announcement from Inspire Pharmaceuticals Inc.

INS117548, a solution designed to treat glaucoma, has entered Phase I clinical trials, according to an announcement made by Inspire Pharmaceuticals Inc.

The Rho kinase inhibitor interferes with the actin cytoskeleton of the trabecular meshwork to lower intraocular pressure (IOP).

This placebo-controlled dose-escalating trial will appraise the compound's safety, efficacy and tolerability in early stage glaucoma or ocular hypertension.

Related Videos

Disrupting the glaucoma treatment paradigm with novel femtosecond laser from ViaLase

2-year data in contralateral eye evaluation gives edge to iStent inject over Hydrus stent

Should endocyclophotocoagulation be considered part of MIGS? Mr Ratnarajan delves in

Investigating the effects of canaloplasty on corneal epithelium

Related Content

Pearls for management of Pseudomonas scleritis

Federal investment and regulatory benefits draw biotech firms to Switzerland

Preservative-free latanoprost as effective as BAK-preserved latanoprost

UK patients with vision loss confused by ‘disjointed’ benefits registration system

Late spring heatwave poses vision risk to populations across Europe

Stating the facts about combination myopia management treatments

Pearls for management of Pseudomonas scleritis

Federal investment and regulatory benefits draw biotech firms to Switzerland

Preservative-free latanoprost as effective as BAK-preserved latanoprost

UK patients with vision loss confused by ‘disjointed’ benefits registration system

Late spring heatwave poses vision risk to populations across Europe

Stating the facts about combination myopia management treatments

Pearls for management of Pseudomonas scleritis

Federal investment and regulatory benefits draw biotech firms to Switzerland

Preservative-free latanoprost as effective as BAK-preserved latanoprost

UK patients with vision loss confused by ‘disjointed’ benefits registration system

Late spring heatwave poses vision risk to populations across Europe

Stating the facts about combination myopia management treatments

Related Content

Pearls for management of Pseudomonas scleritis

Pearls for management of Pseudomonas scleritis

Dr Zeba A. Syed emphasises the importance of performing surgery sooner rather than later for patients with Pseudomonas scleritis

An airport departure board shows a flight to Geneva is boarding. Image credit: ©WD Stockphotos – stock.adobe.com

Federal investment and regulatory benefits draw biotech firms to Switzerland

The country is home to 20% of biotechs headquartered in Europe.

Preservative-free latanoprost as effective as BAK-preserved latanoprost

Preservative-free latanoprost as effective as BAK-preserved latanoprost

Therapeutic has fewer adverse effects in patients with POAG and OHT, study results show

UK patients with vision loss confused by ‘disjointed’ benefits registration system

UK patients with vision loss confused by ‘disjointed’ benefits registration system

Accessibility obstacles could prevent those with sight loss from receiving support and care.

Late spring heatwave poses vision risk to populations across Europe

Late spring heatwave poses vision risk to populations across Europe

What ophthalmologists want patients to know ahead of UK bank holiday.

Stating the facts about combination myopia management treatments

Stating the facts about combination myopia management treatments

Growing evidence supports dual therapy to slow progression.

Terms and Conditions

Do Not Sell My Personal Information

Contact Info

2 Clarke Drive
Cranbury, NJ 08512

© 2023 MJH Life Sciences

All rights reserved.